Substituted Biaryl Sulfonamides Inhibit eIF4E to Treat Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies lack effective targeted treatments for triple negative breast cancer and fibrotic diseases, with existing agents often causing toxicity and side effects, and there is a need for alternatives that inhibit tumor growth without harming normal cells.
Innovation Solution
Development of substituted biaryl sulfonamide compounds that inhibit eIF4E activity, disrupting the eIF4F complex and downregulating protein translation initiation to control cell growth and proliferation, thereby treating cancer and fibrotic disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer therapies are used, then tumor growth can be inhibited, but toxicity and side effects increase
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular structures (biaryl sulfonamides with defined R1-R6 substituents) that selectively target eIF4E in cancer cells. The structured approach to substituent selection creates compounds that exhibit selective toxicity against cancer cells while sparing normal cells, thereby reducing overall toxicity and side effects while maintaining tumor growth inhibition efficacy.
2Reliability
If targeted therapy for triple negative breast cancer is developed, then treatment effectiveness improves, but device complexity increases
Solution Approach 1:
The patent segments the complex task of developing targeted therapy by systematically varying specific molecular components (R1-R6 substituents on the biaryl sulfonamide core). This segmentation allows independent optimization of different structural elements to achieve the desired eIF4E inhibition activity, making the drug discovery process more manageable and systematic rather than attempting to optimize the entire molecule simultaneously.
Solution Approach 2:
The patent employs parameter changes by systematically modifying molecular parameters (substituent types, positions, and configurations) to optimize the compound's interaction with eIF4E. By varying parameters such as the nature of R1-R6 groups and their spatial arrangements, the invention achieves effective inhibition of eIF4E-mediated translation initiation in triple negative breast cancer while managing the complexity through structured parameter variation rather than random molecular design.
3Reliability
If protein translation initiation is inhibited, then cell growth and proliferation are controlled, but manufacturing precision requirements increase
Solution Approach 1:
The patent segments the synthesis process into modular steps corresponding to the assembly of distinct structural components (biaryl core, sulfonamide group, and substituent groups R1-R6). This segmentation allows each component to be synthesized and optimized independently, reducing the overall manufacturing precision requirements compared to synthesizing the complete complex molecule in a single operation. The modular approach enables standardization of synthesis procedures.
Data Source
AI summary
Provided herein are substituted biaryl sulfonamide compounds, pharmaceutical compositions comprising the compounds, methods of their preparation, and methods of their use. The compounds provided herein are useful for the treatment, prevention, and/or amelioration of various disorders, including cancer and proliferative disorders. In one embodiment, the compounds provided herein modulate initiation of protein translation. In one embodiment, the compounds provided herein are used in combination with surgery, radiation therapy, immuno therapy and/or one or more additional anticancer drugs for the treatment, prevention, and/or amelioration of cancer and proliferative disorders.